Compare WVE & DLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WVE | DLX |
|---|---|---|
| Founded | 2012 | 1915 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2015 | 1994 |
| Metric | WVE | DLX |
|---|---|---|
| Price | $6.04 | $25.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 1 |
| Target Price | ★ $29.81 | $23.00 |
| AVG Volume (30 Days) | ★ 2.2M | 345.4K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.99% |
| EPS Growth | N/A | ★ 52.54 |
| EPS | N/A | ★ 1.18 |
| Revenue | $3,704,000.00 | ★ $2,133,200,000.00 |
| Revenue This Year | N/A | $1.35 |
| Revenue Next Year | $85.67 | $1.30 |
| P/E Ratio | ★ N/A | $22.11 |
| Revenue Growth | ★ 149.43 | 0.54 |
| 52 Week Low | $5.02 | $17.76 |
| 52 Week High | $21.73 | $32.07 |
| Indicator | WVE | DLX |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 52.80 |
| Support Level | $5.49 | $25.46 |
| Resistance Level | $6.21 | $26.80 |
| Average True Range (ATR) | 0.25 | 0.80 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 83.54 | 24.21 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Deluxe Corp is principally a payments and data company. Its reportable segments are: Merchant Services, B2B Payments, Data Solutions, and Print. Maximum revenue is derived from its Print segment, which provides printed personal and business checks, business essentials, as well as branded promotional, print, apparel, and digital storefront solutions. The Merchant Services segment provides electronic credit and debit card authorization, payment systems, and processing services. The B2B segment offers treasury management solutions, integrated accounts payable disbursements, and fraud and security services, and the Data Solutions segment offers data, analytics, and marketing services, as well as financial institution profitability reporting and business incorporation services.